Abstract: The present disclosure provides an anti-Staphylococcus aureus specific antibody and the nucleic acid encoding sequence thereof, and uses of the same. The anti-Staphylococcus aureus specific antibody of the present disclosure achieves the effect of treating Staphylococcus aureus infection and enhancing immune cells against Staphylococcus aureus through various efficacy experiments.

Abstract: Rotational molding processes for producing hollow articles include the steps of: a) filling a mold with a polymer composition comprising: i) an organic polymer; and ii) a rotational molding densification accelerator (RMDA) selected from the group consisting of alkoxylated fatty alcohols, alkoxylated fatty esters, alkoxylated fatty amines, alkoxylated fatty amides, and combinations thereof; b) rotating the mold around at least one axis while heating the mold in an oven, thereby fusing the composition and spreading it to the walls of the mold; c) cooling the mold; and d) opening the mold; and e) removing the hollow article from the mold. The rotational molding processes using such polymer composition results in faster densification, which allows for reduction in overall cycle times for making the hollow articles.

Abstract: Provided is an artificial intelligence model training method of an electronic apparatus, the artificial intelligence model training method including primarily updating a second artificial intelligence based on first auscultation sound data and output data of a first artificial intelligence model, updating the first artificial intelligence model based on second auscultation sound data, bioacoustics data with noise removed from the second auscultation sound data, output data of the second artificial intelligence model, and output data of the primarily updated second artificial intelligence model, secondarily updating the primarily updated second artificial intelligence model based on third auscultation sound data and output data of the updated first artificial intelligence model, and tertiarily updating the secondarily updated second artificial intelligence model based on a reward corresponding to output data of the secondarily updated second artificial intelligence model for fourth auscultation sound data.

Abstract: An intelligent medical speech automatic recognition method includes performing a first model training step, a second model training step, a voice receiving step, a signal pre-treatment step and a transforming step. The first model training step is performed to train a generic statement data and a medical statement data of a database to establish a first model. The second model training step is performed to train a medical textbook data of the database to establish a second model. The voice receiving step is performed to receive a speech signal. The signal pre-treatment step is performed to receive the speech signal from the voice receiver and transform the speech signal into a to-be-recognized speech signal. The transforming step is performed to transform and recognize the to-be-recognized speech signal into a complete sentence writing character according to the first model and the second model.

Abstract: A drug carrier with a property of crossing the blood-brain barrier comprises an extracellular vesicle with a human leukocyte antigen-G antibody on its surface. This carrier can serve as a pharmaceutical composition for promoting apoptosis of brain tumor cells, inhibiting growth of brain tumor cells, or reducing expression of O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells. These effects contribute to the treatment of glioblastoma multiforme (GBM).

Abstract: Stabilizer compositions having a stabilizing amount of at least one co-active agent; an ultraviolet light absorber chosen from orthohydroxyphenyl triazine compounds and/or benzoxazinone compounds; and a hindered amine light stabilizer, are provided herein, along with masterbatch concentrates containing same, and processes for using same for stabilizing polymeric organic materials to protect against light and thermal degradation due to exposure to UV irradiation.

Abstract: The present disclosure provides a fusion protein and the nucleic acid encoding sequence thereof, and uses of the same. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.

Abstract: Stabilizer compositions having a stabilizing amount of at least one co-active agent; an ultraviolet light absorber chosen from an ortho-hydroxy benzophenone, and/or an ortho-hydroxyphenyl benzotriazole; and a hindered amine light stabilizer, are provided herein, along with masterbatch concentrates containing same, and processes for using same for stabilizing polymeric organic materials to protect against light and thermal degradation due to exposure to UV irradiation.

Abstract: A cell repair-promoting extracellular vesicle, formed by silicate-induced stem cell secretion, helps express anti-inflammatory, tissue regeneration, and cell repair indicator factors, accelerating cell growth in wound tissue and the wound repair process.

Abstract: A BAG6 specific chimeric antigen receptor, a nucleic acid, a BAG6 specific chimeric antigen receptor expression plasmid, a BAG6 specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the BAG6 specific chimeric antigen receptor expressing cell are provided. The BAG6 specific chimeric antigen receptor specifically binds to BCL2 associated athanogene 6 (BAG6). The nucleic acid encodes the BAG6 specific chimeric antigen receptor. The BAG6 specific chimeric antigen receptor expression plasmid expresses the BAG6 specific chimeric antigen receptor. The BAG6 specific chimeric antigen receptor expressing cell is obtained by transducing the BAG6 specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the BAG6 specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Abstract: Polymer compositions for making a stabilized polymeric articles that are resistant to discoloration upon exposure to UV-C light having: (i) an organic polymeric material; and (ii) a hindered phenol, organic phosphite, or a combination thereof, with the provisos that: (a) the OH group on the aromatic ring of the hindered phenol is flanked by two tertiary hydrocarbyl groups, and (b) the organic phosphite does not have any-OAr group linked directly to the P atom of the phosphite, wherein Ar represents an unsubstituted or substituted aryl group, are provided herein. Reduced discoloration is associated with the use of specific hindered phenols and the organic phosphites compared to other hindered phenols and organic phosphites, even in the absence of other polymer additives including UV absorbers, hindered amine light stabilizers (HALS), metal oxides and/or barium salts.

Abstract: A method for assessing drug-resistant Stenotrophomonas maltophilia includes the following steps. A test sample is provided, wherein the test sample includes a Stenotrophomonas maltophilia. A spectrum analysis step is performed, wherein the test sample is detected by a mass spectrometry method so as to obtain a target mass spectrum data. An assessing step for drug-resistant Stenotrophomonas maltophilia is performed, wherein the target mass spectrum data is analyzed so as to assess whether the Stenotrophomonas maltophilia is susceptible or resistant to a ceftazidime antibiotic. When the Stenotrophomonas maltophilia is susceptible to the ceftazidime, the target mass spectrum data includes a first anti-ceftazidime feature mark, and a mass-to-charge ratio of the first anti-ceftazidime feature mark ranges from 5,965 to 5,975 daltons. When the Stenotrophomonas maltophilia is resistant to the ceftazidime, the target mass spectrum data is without a peak at the first anti-ceftazidime feature mark.

Abstract: A solution for preserving extracellular vesicles/exosomes has a carrier solvent selected from a group consisting of polysorbate 80, sucrose, and polyethylene glycol 3350/4000; and a stabilizer selected from a group consisting of salts, amino acids, and amino acid salts; wherein the pH of the preservation solution ranges from 5 to 7.4.

Abstract: The present disclosure provides an anti-tumor antigen nanobody that specifically binds to a human leukocyte antigen-G. The present disclosure also provides the nucleic acid sequence of the anti-tumor antigen nanobody, use of the anti-tumor antigen nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of HLA-G.

Abstract: Present invention is related to a tumor microenvironment on chip or a biochip for cell therapy having a carrier, a first cell or tissue culture area and a second cell or tissue area imbedded within the carrier. The present invention provides a biochip successfully cooperating micro fluidic technology and cell culture achieving the goal for detecting or testing the function of cell therapy for cancer or tumor.

Abstract: Provided is a method for classifying diseases using artificial intelligence (AI) of an electronic apparatus. The method for classifying diseases may comprise obtaining auscultation sound data and auscultation position data, obtaining feature information based on the auscultation sound data and obtaining auscultation position information based on the auscultation position data, generating combined information by combining the feature information and the auscultation position information, and identifying at least one of disease information corresponding to the combined information, by using an AI model.

Abstract: A method for assessing drug-resistant Klebsiella pneumoniae includes the following steps. A test sample is provided, wherein the test sample includes a Klebsiella pneumoniae. A spectrum analysis step is performed, wherein the test sample is detected by a mass spectrometry method so as to obtain a target mass spectrum data. An assessing step for drug-resistant Klebsiella pneumoniae is performed, wherein the target mass spectrum data is analyzed so as to assess whether the Klebsiella pneumoniae is resistant to a carbapenem antibiotic or a colistin or not. When the Klebsiella pneumoniae is resistant to the carbapenem antibiotic, the target mass spectrum data includes a first anti-carbapenem feature mark, and when the Klebsiella pneumoniae is resistant to the colistin, the target mass spectrum data includes a first anti-colistin feature mark.

Abstract: Provided is a method for classifying diseases using artificial intelligence (AI) of an electronic apparatus. The method for classifying diseases may comprise obtaining auscultation sound data and auscultation position data, obtaining feature information based on the auscultation sound data and obtaining auscultation position information based on the auscultation position data, generating combined information by combining the feature information and the auscultation position information, and identifying at least one of disease information corresponding to the combined information, by using an AI model.

Abstract: The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 ?. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 ?.